-
摘要: 目的:研究输血对初诊多发性骨髓瘤(MM)患者预后的影响。方法:采用匹配病例对照研究方法,将2012-06-2016-12首次诊断的84例MM患者根据是否输血分为输血组(42例)和非输血组(42例)。观察各组总生存率(OS)及无进展生存率(PFS)。结果:输血患者的血红蛋白水平比非输血组患者低。输血组患者硼替佐米的使用率更高。单因素分析中采取输血的患者PFS更低;年龄、ISS分期、血小板水平、血红蛋白水平、血清肌酐水平、血清β2-MG、血清钙和沙利度胺药物的使用是OS和PFS的共同影响因素。采用多变量分析,高龄(≥60),高血清钙(≥2.75 mmol/L)是影响MM患者OS的危险因素,高血小板水平(≥100×109/L)和沙利度胺药物的使用是OS的保护因素。Ig分型和沙利度胺应用是MM患者PFS的独立预后因素。输血不是MM患者OS和PFS的独立预后因素。结论:沙利度胺药物能够有效提高患者的OS和PFS。输血不影响MM患者的PFS以及OS,不是MM患者预后的危险因素。Abstract: Objective:To analysis the prognosis effect of blood transfusion on multiple myeloma (MM) patients. Method:A case-control study of 84 MM patients who were diagnosed first in our hospital from June 2012 to December 2016 were divided into transfusion group (n=42) and non-transfusion group (n=42). The overall survival (OS) and progression-free survival (PFS) were observed. Result:Hemoglobin levels in patients with transfusion were lower than that in non-transfusion patients. The percentage of bortezomib using was higher in transfusion group. The age, ISS stage, platelet level, hemoglobin level, serum creatinine level, serum β2-MG, serum calcium and thalidomide were the common factors of OS and PFS in univariate analysis. In multivariate analysis, older age (≥ 60) and higher serum calcium (≥ 2.75 mmol/L) were the risk factors for OS in MM patients. Higher platelet levels (≥ 100×109/L) and use of thalidomide were protection factors for OS. Ig isotype and thalidomide were the independent prognostic factors for PFS in MM patients. Blood transfusion was not an independent prognostic factor for OS and PFS in MM patients. Conclusion:Thalidomide could effectively improve OS and PFS in MM patients. Blood transfusion would have no effect on PFS and OS of MM patients, and not be the risk factor for the prognosis of MM patients.
-
Key words:
- transfusion /
- multiple myeloma /
- survival analysis /
- prognosis
-
-
[1] Ejaz A, Spolverato G, Kim Y, et al. Impact of blood transfusions and transfusion practices on long-term outcome following hepatopancreaticobiliary surgery[J]. J Gastrointest Surg, 2015, 19:887-896.
[2] Cata J P, Wang H, Gottumukkala V, et al. Inflammatory response, immunosuppression, and cancer recurrence after perioperative blood transfusions[J]. Br J Anaesth, 2013, 110:690-701.
[3] 隋鑫,赵丹,林红梅,等.放疗联合免疫治疗癌症的研究进展[J].中华放射肿瘤学杂志, 2016, 25(10):1135-1138.
[4] Elmi M, Mahar A, Kagedan D, et al. The impact of blood transfusion on perioperative outcomes following gastric cancer resection:an analysis of the American College of Surgeons National Surgical Quality Improvement Program database[J]. Can J Surg, 2016, 59:322-322.
[5] Park YH, Kim YJ, Kang SH, et al. Association between perioperative blood transfusion and oncologic outcomes after curative surgery for renal cell carcinoma[J]. J Cancer, 2016, 7:965-965.
[6] Squires MH, Kooby DA, Poultsides GA, et al. Effect of perioperative transfusion on recurrence and survival after gastric cancer resection:a 7-institution analysis of 765 patients from the US Gastric Cancer Collaborative[J]. J Am Coll Surg, 2015, 221:767-777.
[7] Sui W, Onyeji IC, Matulay JT, et al. Perioperative blood transfusion predicts short term morbidity after nephrectomy[J]. Can J Urol, 2016, 23:8348-8355.
[8] Zhou HY, Yi W, Wang J, et al. Association of perioperative allogeneic blood transfusions and prognosis of patients with gastric cancer after curative gastrectomy[J]. Am J of Surg, 2014, 208:80-87.
[9] Alkayed K, Al Hmood A, Madanat F. Prognostic effect of blood transfusion in children with acute lymphoblastic leukemia[J]. Blood Res, 2013, 48:133-138.
[10] Heddle NM, Cook RJ, Arnold DM, et al. Effect of short-term vs. long-term blood storage on mortality after transfusion[J]. N Engl J Med, 2016, 375:1937-1945.
[11] Jaime-Pérez JC, Colunga-Pedraza PR, Gómez-Almaguer D. Is the number of blood products transfused associated with lower survival in children with acute lymphoblastic leukemia[J]. Pediatr Blood Cancer, 2011, 57:217-223.
[12] 吴文忠,周志刚,陈亚峰,等.多发性骨髓瘤贫血的发病机制及治疗研究进展[J].世界临床药物, 2016, 37(8):572-576.
[13] 邸平,潘玉玲,王成彬.鉴别诊断多发性骨髓瘤实验方法新进展[J].医学综述, 2014, 20(6):1012-1014.
[14] 顾雪萍,综述,周泽平.血小板对固有免疫和适应性免疫的调节作用进展[J].中国免疫学杂志, 2015, 31(11):1569-1584.
[15] Lu J, Chen W, Huo Y, et al. Clinical features and treatment outcome in newly diagnosed Chinese patients with multiple myeloma:results of a multicenter analysis[J]. Blood Cancer J, 2014, 4:239-239.
[16] quina CT, Blumberg N, Becerra AZ, et al. Association among blood transfusion, sepsis, and decreased long-term survival after colon cancer resection[J]. Ann Surg, 2017, 266:311-317.
[17] Kanda M, Kobayashi D, Tanaka C, et al. Adverse prognostic impact of perioperative allogeneic transfusion on patients with stage II/III gastric cancer[J]. Gastric Cancer, 2016, 19:255-263.
[18] Rink M, Soave A, Dahlem R, et al. Impact of perioperative allogenic blood transfusion on survival after radical nephroureterectomy for upper tract urothelial carcinoma[J]. Clin Genitourinary Cancer, 2016, 14:96-104.
[19] Wang T, Luo L, Huang H, et al. Perioperative blood transfusion is associated with worse clinical outcomes in resected lung cancer[J]. Ann Thoracic Surgery, 2014, 97:1827-1837.
[20] 赵学涛,杨从容,任晓亮,等.红细胞输注对肝癌患者CD4+T辅助细胞免疫功能的影响[J].河北医科大学学报, 2015, 36(7):803-803.
[21] Kouroukis C T, Baldassarre F G, Haynes A E, et al. Bortezomib in multiple myeloma:a practice guideline[J]. Clin Oncol, 2014, 26:110-119.
[22] Ghattass K, Assah R, El-Sabban M, et al. Targeting hypoxia for sensitization of tumors to radio-and chemotherapy[J]. Curr Cancer Drug Targets, 2013, 13:670-685.
[23] Liu F, Mu J, Xing B. Recent advances on the development of pharmacotherapeutic agents on the basis of human serum albumin[J]. Current Pharmaceutical Design, 2015, 21:1866-1888.
[24] Sleep D. Albumin and its application in drug delivery[J]. Expert Opinion Drug Delivery, 2015, 12:793-812.
[25] Losem C, Koenigsmann M, Rudolph C. Biosimilar retacrit?(epoetin zeta) in the treatment of chemotherapy-induced symptomatic anemia in hematology and oncology in germany (OrheO)-non-interventional study[J]. Onco Targets Therapy, 2017, 10:1295-1305.
-
计量
- 文章访问数: 187
- PDF下载数: 271
- 施引文献: 0
下载: